Systemic therapy for breast cancer

Changing trends, 1980

Research output: Contribution to journalArticle

Abstract

The 1970s were a decade of change in the treatment of breast cancer. In the management of metastatic disease, hormone receptor assays and two new drugs, tamoxifen and aminoglutethimidine, have caused a reassessment of classical hormonal therapeutic strategies, while combination chemotherapy was found to produce objective antitumor responses and excellent palliation in a majority of patients. In the 1980s clinical investigation of strategies employing mutually non-cross-resistant drug combinations, chemohormonal, or chemoimmunotherapeutic approaches could result in more complete and durable remissions. Immunotherapy and interferon remain investigational approaches of some promise that have yet to find established roles in the treatment of metastatic breast cancer. In the area of adjuvant systemic therapies in primary breast cancer, answers to perplexing questions have begun to emerge. The apparent lack of effectiveness of adjuvant chemotherapy in postmenopausal patients with Stage II breast cancer appears to be a problem of inadequate doses administered to these women in the first two large-scale adjuvant trials. At a follow-up period five years after mastectomy, definite advantage in both overall and relapse free survival are still evident in adjuvant-chemotherapy-treated premenopausal patients compared with patients having radical mastectomy alone. Current trials using more aggressive chemotherapy appear to show equivalent benefit in premenopausal and postmenopausal women. The use of adjuvant radiation therapy before adjuvant chemotherapy appears to be detrimental. Whether newer approaches, such as adjuvant radiation therapy after adjuvant chemotherapy, chemohormonal therapy, or chemoimmunotherapy, are superior to aggressive adjuvant chemotherapy alone remains to be determined through continuing controlled, randomized adjuvant therapeutic trials.

Original languageEnglish
Pages (from-to)48-53
Number of pages6
JournalComprehensive Therapy
Volume6
Issue number10
StatePublished - Dec 1 1980

Fingerprint

Adjuvant Chemotherapy
Breast Neoplasms
Radiotherapy
Therapeutics
Radical Mastectomy
Mastectomy
Drug Combinations
Tamoxifen
Disease Management
Combination Drug Therapy
Immunotherapy
Interferons
Hormones
Recurrence
Drug Therapy
Survival
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Systemic therapy for breast cancer : Changing trends, 1980. / Vogel, Charles.

In: Comprehensive Therapy, Vol. 6, No. 10, 01.12.1980, p. 48-53.

Research output: Contribution to journalArticle

@article{d4e254cecaf24a52a7efe0fe5a8b4fbf,
title = "Systemic therapy for breast cancer: Changing trends, 1980",
abstract = "The 1970s were a decade of change in the treatment of breast cancer. In the management of metastatic disease, hormone receptor assays and two new drugs, tamoxifen and aminoglutethimidine, have caused a reassessment of classical hormonal therapeutic strategies, while combination chemotherapy was found to produce objective antitumor responses and excellent palliation in a majority of patients. In the 1980s clinical investigation of strategies employing mutually non-cross-resistant drug combinations, chemohormonal, or chemoimmunotherapeutic approaches could result in more complete and durable remissions. Immunotherapy and interferon remain investigational approaches of some promise that have yet to find established roles in the treatment of metastatic breast cancer. In the area of adjuvant systemic therapies in primary breast cancer, answers to perplexing questions have begun to emerge. The apparent lack of effectiveness of adjuvant chemotherapy in postmenopausal patients with Stage II breast cancer appears to be a problem of inadequate doses administered to these women in the first two large-scale adjuvant trials. At a follow-up period five years after mastectomy, definite advantage in both overall and relapse free survival are still evident in adjuvant-chemotherapy-treated premenopausal patients compared with patients having radical mastectomy alone. Current trials using more aggressive chemotherapy appear to show equivalent benefit in premenopausal and postmenopausal women. The use of adjuvant radiation therapy before adjuvant chemotherapy appears to be detrimental. Whether newer approaches, such as adjuvant radiation therapy after adjuvant chemotherapy, chemohormonal therapy, or chemoimmunotherapy, are superior to aggressive adjuvant chemotherapy alone remains to be determined through continuing controlled, randomized adjuvant therapeutic trials.",
author = "Charles Vogel",
year = "1980",
month = "12",
day = "1",
language = "English",
volume = "6",
pages = "48--53",
journal = "Comprehensive Therapy",
issn = "0098-8243",
publisher = "Humana Press",
number = "10",

}

TY - JOUR

T1 - Systemic therapy for breast cancer

T2 - Changing trends, 1980

AU - Vogel, Charles

PY - 1980/12/1

Y1 - 1980/12/1

N2 - The 1970s were a decade of change in the treatment of breast cancer. In the management of metastatic disease, hormone receptor assays and two new drugs, tamoxifen and aminoglutethimidine, have caused a reassessment of classical hormonal therapeutic strategies, while combination chemotherapy was found to produce objective antitumor responses and excellent palliation in a majority of patients. In the 1980s clinical investigation of strategies employing mutually non-cross-resistant drug combinations, chemohormonal, or chemoimmunotherapeutic approaches could result in more complete and durable remissions. Immunotherapy and interferon remain investigational approaches of some promise that have yet to find established roles in the treatment of metastatic breast cancer. In the area of adjuvant systemic therapies in primary breast cancer, answers to perplexing questions have begun to emerge. The apparent lack of effectiveness of adjuvant chemotherapy in postmenopausal patients with Stage II breast cancer appears to be a problem of inadequate doses administered to these women in the first two large-scale adjuvant trials. At a follow-up period five years after mastectomy, definite advantage in both overall and relapse free survival are still evident in adjuvant-chemotherapy-treated premenopausal patients compared with patients having radical mastectomy alone. Current trials using more aggressive chemotherapy appear to show equivalent benefit in premenopausal and postmenopausal women. The use of adjuvant radiation therapy before adjuvant chemotherapy appears to be detrimental. Whether newer approaches, such as adjuvant radiation therapy after adjuvant chemotherapy, chemohormonal therapy, or chemoimmunotherapy, are superior to aggressive adjuvant chemotherapy alone remains to be determined through continuing controlled, randomized adjuvant therapeutic trials.

AB - The 1970s were a decade of change in the treatment of breast cancer. In the management of metastatic disease, hormone receptor assays and two new drugs, tamoxifen and aminoglutethimidine, have caused a reassessment of classical hormonal therapeutic strategies, while combination chemotherapy was found to produce objective antitumor responses and excellent palliation in a majority of patients. In the 1980s clinical investigation of strategies employing mutually non-cross-resistant drug combinations, chemohormonal, or chemoimmunotherapeutic approaches could result in more complete and durable remissions. Immunotherapy and interferon remain investigational approaches of some promise that have yet to find established roles in the treatment of metastatic breast cancer. In the area of adjuvant systemic therapies in primary breast cancer, answers to perplexing questions have begun to emerge. The apparent lack of effectiveness of adjuvant chemotherapy in postmenopausal patients with Stage II breast cancer appears to be a problem of inadequate doses administered to these women in the first two large-scale adjuvant trials. At a follow-up period five years after mastectomy, definite advantage in both overall and relapse free survival are still evident in adjuvant-chemotherapy-treated premenopausal patients compared with patients having radical mastectomy alone. Current trials using more aggressive chemotherapy appear to show equivalent benefit in premenopausal and postmenopausal women. The use of adjuvant radiation therapy before adjuvant chemotherapy appears to be detrimental. Whether newer approaches, such as adjuvant radiation therapy after adjuvant chemotherapy, chemohormonal therapy, or chemoimmunotherapy, are superior to aggressive adjuvant chemotherapy alone remains to be determined through continuing controlled, randomized adjuvant therapeutic trials.

UR - http://www.scopus.com/inward/record.url?scp=0019219982&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019219982&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 48

EP - 53

JO - Comprehensive Therapy

JF - Comprehensive Therapy

SN - 0098-8243

IS - 10

ER -